Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00041
|
|||||
| Drug Name |
Pralatrexate
|
|||||
| Synonyms |
Folotyn (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Breast cancer [ICD11: 2C60-2C6Z] | Approved | [1] | |||
| Peripheral T-cell lymphoma [ICD11: 2A90.C] | Approved | [1] | ||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H23N7O5
|
|||||
| Canonical SMILES |
C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
|
|||||
| InChI |
InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1
|
|||||
| InChIKey |
OGSBUKJUDHAQEA-WMCAAGNKSA-N
|
|||||
| CAS Number |
CAS 146464-95-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 477.5 | Topological Polar Surface Area | 207 | ||
| Heavy Atom Count | 35 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 11 | |||
| XLogP |
-0.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10249810
, 103771482
, 104418267
, 124950714
, 126666101
, 131408688
, 134223179
, 135692165
, 136367814
, 137248707
, 141792755
, 144206459
, 144236486
, 14761163
, 14907808
, 152106310
, 152258219
, 152344466
, 160646081
, 160647055
, 164044033
, 164232763
, 164764489
, 175427094
, 175437712
, 176484650
, 178103446
, 180191813
, 184527271
, 186014781
, 198993109
, 223392464
, 223659651
, 223702389
, 225255488
, 226410872
, 240035409
, 241036657
, 243124404
, 249868098
, 252069088
, 252214139
, 252473148
, 46225076
, 47207252
, 57346701
, 76049103
, 99437279
|
|||||
| ChEBI ID |
CHEBI:71223
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | FLOT1 | Transporter Info | Folate transporter 1 | Substrate | [2] | |
| PCFT | Transporter Info | Proton-coupled folate transporter | Substrate | [2] | ||
| References | ||||||
| 1 | Pralatrexate was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.